Cardinal Health Inc (CAH) Stock Price Prediction: 2025, 2026, 2030

The post Cardinal Health Inc (CAH) Stock Price Prediction: 2025, 2026, 2030 by Marc Guberti appeared first on Benzinga. Visit Benzinga to get more great content like this.

Analysts are saying that Cardinal Health could rise by 2030. Bullish on CAH? Invest in Cardinal Health on SoFi with no commissions. If it’s your first time signing up for SoFi, you’ll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025.

Cardinal Health Inc. (CAH) is one of the Big Three drug distributors. Few competitors can keep up with its scale, but the company’s razor-thin margins leave little room for error. An aging population can boost demand for the already growing specialty drug industry, which could give the stock a boost.

In this article, we’ll look at CAH’s latest share price, Wall Street sentiment, multiyear price forecasts, and the key factors that are playing a critical role in the company’s path going forward.

Current Stock Overview

Market Cap: $50.75 billion

Trailing P/E Ratio: 31.60

Forward P/E Ratio: 21.51

1-Year Return: 74%

2025 YTD: 81%

CAH has a consensus Buy rating from 18 analysts, according to Benzinga. The average price target is $167.61 per share. The highest price target is $225, and the lowest is $85. The three most recent ratings suggest a near-term average target of $218.67. 

Quick Snapshot Table of Predictions & Methodology for Forecasting

Bull & Bear Case

An aging population and strong growth from specialty drugs are tailwinds for Cardinal Health, but low margins are a significant issue.

Bull Case

• Alongside McKesson Corp. and Cencora, Inc., Cardinal Health is one of the Big Three U.S. drug distributors, giving it a level of scale that few competitors can match.
• Specialty pharmaceuticals are a fast-growing area of the medical industry, and the company has seen high growth rates from this segment.
• An aging population can boost demand and increase volume for Cardinal Health’s services and products.

Bear Case

• CAH’s P/E ratio is higher than almost 80% of medical distribution stocks, which suggests the stock may have limited upside. 
• The drug distribution industry has very low margins, which is why CAH’s net profit margin is typically below 1%, suggesting limited protection in the event prices go down or costs go up.
• CAH depends on the global supply chain, and any disruptions can weaken its already low profit margins.

Stock Price Prediction for 2025

CoinCodex’s forecast suggests a higher probability of CAH stock gaining value than seeing its stock price go down. High growth rates from the specialty pharmaceutical industry can lead to this forecast, especially with Cardinal Health’s scale exceeding most of its competitors. 

Stock Price Prediction for 2026

CoinCodex projects CAH stock rallying in 2026, possibly due to the continued growth of the specialty pharmaceutical industry. An aging population can boost sales and profit margins as well.

Stock Price Prediction for 2030

CoinCodex projects meaningful growth for CAH stock in 2030, possibly due to long-term tailwinds of an aging population and specialty drugs gaining momentum. Supply chain issues may not be as significant in 2030, which could help Cardinal Health reach its forecasted price target.

Investment Considerations

After more than 50 years in business, Cardinal Health is an industry leader with the scale to ensure its dominance. The company already has two tailwinds in the fast-growing specialty drugs market and an aging population. Any positive developments for its margins can be a further catalyst for its stock.

A high valuation relative to its peers, however, suggests that any erosion of those razor-thin margins could result in a pullback for shares.

The post Cardinal Health Inc (CAH) Stock Price Prediction: 2025, 2026, 2030 by Marc Guberti appeared first on Benzinga. Visit Benzinga to get more great content like this.